Hyperspectral Imaging for Prediction of Preeclampsia

Sponsor
Heidelberg University
Study ID
NCT07106294
Status
Recruiting
Apply to this trial

Conditions

  • Preeclampsia
  • Preeclampsia (PE) Risk

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Accepted

Study Details

Preeclampsia is a hypertensive pregnancy disorder that can quickly lead to serious, potentially life-threatening outcomes for both the mother and the fetus. Typical features of preeclampsia are by endothelial and microvascular dysfunctionsNotably, such impairments in endothelial function may precede preeclampsia diagnosis and canpersist for years postpartum. In clinical practice, however, no predictive methods have yet been established that specifically reflect endothelial dysfunction in the context of preeclampsia. Hyperspectral imaging represents a new and non-invasive imaging modality that allows contact-free visualization of peripheral microcirculatory dynamics and tissue perfusion. Despite its growing use in other medical fields, this technology has not yet been systematically studied to determine its predictive potential in preeclampsia. The HIPPA project (Systematic Evaluation of Hyperspectral Analysis for Prediction of Preeclampsia) is a prospective observational study to evaluate the applicability of hyperspectral imaging as a new tool for prediction of preeclampsia.

Key Dates

First listed
Aug 6, 2025
Start date
Aug 21, 2025
Status verified
Aug 2025
Primary completion
Jul 1, 2027
Completion
Jul 1, 2027

Study Design

Enrollment
1,430 participants (estimated)

Arms

  • Arm: First trimester
    patients scheduled for routine first trimester ultrasound assessment
  • Arm: Second trimester
    patients scheduled for routine anomaly scan in second trimester

Primary Outcome Measure

Number of patients with Preeclampsia [ Time Frame: up to one week after delivery ]

Central Contacts

Related Studies